Tetrabenazine in the treatment of hyperkinetic movement disorders;Tetrabenazin in der behandlung hyperkinetischer bewegungsstörungen

Psychopharmakotherapie

Volumn 17, Issue 2, 2010, Pages 85-90

  Schrader, Christoph ^a   Dengler, Reinhard ^a   Dressler, Dirk ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chorea; Dystonia; Huntington's disease; Hyperkinetic movement disorders; Myoclonus; Pharmacology; Tardive dyskinesias; Tetrabenazine; Tic

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; TETRABENAZINE;

CHOREA; DEPRESSION; DYSPHAGIA; DYSTONIA; HUNTINGTON CHOREA; HYPERKINESIA; MYOCLONUS; PARKINSONISM; REVIEW; TARDIVE DYSKINESIA; TIC;

EID: 77951590615     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372 (Pubitemid 43739938)
2. Ashcroft GW, MacDougall EJ, Barker PA. A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia. J Ment Sci 1961;107:287-293
3. Brandrup E. Reserpin og tetrabenacin ved chorea Huntington. Nord Med 1960;4:968-969
4. Burke RE, Fahn S, et al. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology 1981;31:1022-1025 (Pubitemid 11061744)
5. Burke RE, Reches A, Traub MM, Ilson J, et al. Tetrabenazine induces acute dystonic reactions. Ann Neurol 1985;17:200-202 (Pubitemid 15170444)
6. Chatterjee A, Frucht SJ. Tetrabenazine in the treatment of severe pediatric chorea. Mov Disord 2003;18:703-706
7. Erickson JD, Schafer MK, Bonner TI, Eiden LE, et al. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci U S A 1996;93:5166-5171
8. Frank S, Ondo W, Fahn S, Hunter C, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008;31:127-133 (Pubitemid 351787108)
9. Garcia Ruiz PJ, Mena MA, Sanchez BV, Diaz NW, et al. Cerebrospinal fluid homovanillic acid is reduced in untreated Huntington's disease. Clin Neuropharmacol 1995;18:58-63.
10. Gimenez-Roldan S, Mateo D. Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements. Neurologia 1989;4:282-287 (Pubitemid 19278289)
11. Gonzalez AM, Walther D, Pazos A, Uhl GR. Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res Mol Brain Res 1994;22:219-226 (Pubitemid 24063643)
12. Jain S, Greene PE, Frucht SJ. Tetrabenazine therapy of pediatric hyperkinetic movement disorders. Mov Disord 2006;21:1966-1972 (Pubitemid 44848947)
13. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-362 (Pubitemid 27087603)
14. Jankovic J, Caskey TC, Stout JT, Butler IJ. Lesch-Nyhan syndrome: a study of motor behaviour and cerebrospinal fluid neurotransmitters. Ann Neurol 1988;23:466-469
15. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988;38:391-394 (Pubitemid 18083674)
16. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22:193-197 (Pubitemid 46374760)
17. Kenney C, Hunter C, Mejia N, Jankovic J. Tetrabenazine in the treatment of Tourette syndrome. J Ped Neurol 2007;5:9-13.
18. Kidd DW, McLellan DL. Self-poisoning with tetrabenazine. Br J Clin Pract 1972;26:179-180
19. Kingston D. Tetrabenazine for involuntary movement disorders. Med J Aust 1979;1:628-630 (Pubitemid 10224909)
20. Lane JD, Smith JE, Shea PA, McBride WJ. Neurochemical changes following the administration of depleters of biogenic monoamines. Life Sci 1976;19:1663-1667
21. Login IS, Cronin MJ, MacLeod RM. Tetrabenazine has properties of a dopamine receptor antagonist. Ann Neurol 1982;12:257-262
22. Mateo D, Munoz-Blanco JL, Gimenez-Roldan S. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. Clin Neuropharmacol 1992;15:63-68
23. McLellan DL. The suppression of involuntary movements with tetrabenazine. Scott Med J 1972;17:367-370
24. McLellan DL, et al. A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. Lancet 1974;1:104-107
25. Mehvar R, Jamali F, Watson MW, Skelton D. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. Drug Metab Dispos 1987;15:250-255
26. Mestre T, Ferreira J, Coelho MM, Rosa M, et al. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009;CD006456.
27. Mikkelsen BO. Tolerance of tetrabenazine during long-term treatment. Acta Neurol Scand 1983;68:57-60.
28. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156:1279-1281
29. Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol 2002;25:300-302 (Pubitemid 36025267)
30. Ossemann M, Sindic CJ, Laterre C. Tetrabenazine as a cause of neuroleptic malignant syndrome. Mov Disord 1996;11:95.
31. Paleacu D. Tetrabenazine in the treatment of Huntington's disease. Neuropsychiatr Dis Treat 2007;3:545-551
32. Paleacu D, Giladi N, Moore O, Stern A, et al. Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 2004;27:230-233 (Pubitemid 39447220)
33. Pearson SJ, Reynolds GP. Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology 1988;27:717-719
34. Pettibone DJ, et al. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur J Pharmacol 1984;102:425-430
35. Petzinger GM, Bressman SB. A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment. Mov Disord 1997;12:246-248 (Pubitemid 27152033)
36. Porta M, Sassi M, Cavallazzi M, Fornari M, et al. Tourette's syndrome and role of tetrabenazine: review and personal experience. Clin Drug Investig 2008;28:443-459
37. Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther 1959;127:103-109
38. Reches A, Burke RE, Kuhn CM, Hassan MN, et al. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther 1983;225:515-521 (Pubitemid 13070863)
39. Roberts MS, McLean S, Millingen KS, Galloway HM. The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders. Eur J Clin Pharmacol 1986;29:703-708 (Pubitemid 16155744)
40. Roberts MS, Watson HM, McLean S, Millingen KS. Determination of therapeutic plasma concentrations of tetrabenazine and an active metabolite by high-performance liquid chromatography. J Chromatogr 1981;226:175-182 (Pubitemid 12223711)
41. Sattes H. The treatment of chorea minor with the monoamine liberator "Nitoman". Psychiatr Neurol (Basel) 1960;140:13-19
42. Savani AA, Login IS. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2007;68:797. (Pubitemid 46667918)
43. Scherman D. Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions. J Neurochem 1986;47:331-339 (Pubitemid 16052845)
44. Scherman D, Henry JP. Acido-basic properties of the catecholamine uptake inhibitors tetrabenazine and dihydrotetrabenazine. Biochimie 1982;64:915-921 (Pubitemid 13205854)
45. Snaith RP, Warren HD. Letter: Treatment of Huntington's chorea with tetrabenazine. Lancet 1974;1:413-414
46. Stevens E, et al. Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia. intensive Care Med 1998;24:369-371 (Pubitemid 28203889)
47. Stumpf W. Untersuchungen über "Nitoman". Psychiatr Neurol (Basel) 1960;140:63-68